biostudies-literatureZhang XChongqing Jingyin Bioscience Co., Ltd.Chinese Academy of Medical Sciences Innovation Fund for Medical SciencesMinistry of Science and Technology of the People&apos;s Republic of ChinaBeijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science ParkChinese Stroke AssociationNational Natural Science Foundation of ChinaSalubrisCapital&apos;s Funds for Health Improvement and ResearchNational Science and Technology Major Project541-550https://www.ebi.ac.uk/biostudies/studies/S-EPMC11732837biostudies-literatureUnknown9(5)<h4>Objectives</h4>Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke is limited, especially those elder than 80 years. This study aimed to explore the efficacy and safety of dual antiplatelet therapy (DAPT) in old-old patients compared with younger patients in the ticagrelor or Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events-II (CHANCE-2) trial.<h4>Methods</h4>CHANCE-2 was a randomised, double-blind, placebo-controlled trial in China involving patients with high-risk transient ischaemic attack or minor stroke with CYP2C19 loss-of-function alleles. In our substudy, all enrolled patients were stratified by age: old-old (≥80 years), young-old (65-80 years) and younger (<65 years). The primary outcomes were stroke Stroke and vascular neurologyEfficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial.PMC117328372020-1-2041818709052017ZX09304018U20A20358821013572019-I2M-5-029Li HJing JLi JWang ALiu LXie XXu QHan XJohnston SCGong XMeng XZhao XJiang YLi ZZhang XChen WBath PMLin JWang YfalseEfficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a subgroup analysis of the CHANCE-2 trial.<h4>Objectives</h4>Evidence of the optimal antiplatelet therapy for elderly patients who had a stroke is limited, especially those elder than 80 years. This study aimed to explore the efficacy and safety of dual antiplatelet therapy (DAPT) in old-old patients compared with younger patients in the ticagrelor or Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events-II (CHANCE-2) trial.<h4>Methods</h4>CHANCE-2 was a randomised, double-blind, placebo-controlled trial in China involving patients with high-risk transient ischaemic attack or minor stroke with CYP2C19 loss-of-function alleles. In our substudy, all enrolled patients were stratified by age: old-old (≥80 years), young-old (65-80 years) and younger (<65 years). The primary outcomes were stroke 2024-01-01T00:00:00Z2024 Nov2026-06-01T09:00:04.957Z2025-04-06T01:14:10.607ZS-EPMC117328373828648510.1136/svn-2023-002450